McConkey B, Situnayake R D
Department of Medicine, Dudley Road Hospital, Birmingham, UK.
J Rheumatol. 1988 Jan;15(1):46-50.
A patient with rheumatoid arthritis (RA) experienced great improvement in her RA when given antituberculous treatment for pulmonary tuberculosis (TB). Two of the drugs used in TB, rifampicin and isoniazid, include immunomodulatory effects among their properties. To investigate whether these drugs have any effect in RA, we studied 20 patients who were given either rifampicin 600 mg daily (10 patients) or rifampicin 600 mg with isoniazid 300 mg daily (10 patients). Eighteen patients completed at least 3 months' treatment. Six of the 7 patients with early RA (less than 3 years) improved; their median erythrocyte sedimentation rate fell from 43.5-10 mm/h (p = 0.036) and median serum C-reactive protein from 40-0 mg/l (p = 0.036). Eleven patients with longer histories of RA did not improve. Our results suggest rifampicin with or without isoniazid may be effective in RA.
一名类风湿性关节炎(RA)患者在接受肺结核(TB)抗结核治疗时,其类风湿性关节炎病情有了显著改善。用于治疗肺结核的两种药物,利福平和异烟肼,在其特性中具有免疫调节作用。为了研究这些药物对类风湿性关节炎是否有任何影响,我们对20名患者进行了研究,其中10名患者每天服用600毫克利福平,另外10名患者每天服用600毫克利福平加300毫克异烟肼。18名患者完成了至少3个月的治疗。7名早期类风湿性关节炎(病程小于3年)患者中有6名病情改善;他们的红细胞沉降率中位数从43.5降至10毫米/小时(p = 0.036),血清C反应蛋白中位数从40降至0毫克/升(p = 0.036)。11名类风湿性关节炎病程较长的患者病情没有改善。我们的结果表明,利福平无论是否联合异烟肼,可能对类风湿性关节炎有效。